CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.95×, lower than 95% of its Biotechnology peers (median 5.71×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
775.88MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.25xvs all stocks
52-Week Change
148.03%vs all stocks
Market Capitalization
775.88MUSDvs all stocks (USD)
Enterprise Value
603.53MUSDvs all stocks (USD)
Forward P/E
-11.85xvs Biotechnology peers
Enterprise to EBITDA
-10.40xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-29.21%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-58.05MUSDvs all stocks (USD)
Net Income (TTM)
-114.04MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-47.02MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-54.88MUSDvs all stocks (USD)
Pre-tax Income
-54.65MUSDFY2025 · Dec 31, 2025Net Income
-54.65MUSDFY2025 · Dec 31, 2025EBIT
-53.83MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-53.19MUSDFY2025 · Dec 31, 2025Research & Development
23.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
31.88MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
819.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.25USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.25USDFY2025 · Dec 31, 2025Basic Shares Outstanding
43.59MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
43.59MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-54.65MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-46.28MUSDFY2025 · Dec 31, 2025Free Cash Flow
-46.29MUSDDerived from operating cash flow minus capital expenditure. This filing charges 228K of depreciation against 4K of capital expenditure, and its own free-cash-flow line reads -49.47M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
20.95MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-54.65MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
228.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.76MUSDFY2025 · Dec 31, 2025Other Non-cash Items
460.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.08MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
-4.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-24.75MUSDFY2025 · Dec 31, 2025Sale of Investments
30.87MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
6.11MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
50.14MUSDFY2025 · Dec 31, 2025Shares Outstanding
102.66MSharesUpdated Sep 26, 2026Float Shares
74.69MSharesUpdated Sep 26, 2026Shares Short
15.99MSharesUpdated Sep 26, 2026Short Ratio
10.23daysvs all stocks
Short % of Shares Outstanding
15.63%vs all stocks
% Held by Insiders
0.91%vs all stocks
% Held by Institutions
82.06%vs all stocks
Total Cash (MRQ)
187.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.82USDUpdated Sep 26, 2026Total Debt (MRQ)
14.95MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.9530xvs Biotechnology peers
Book Value per Share (MRQ)
-0.1430USDUpdated Sep 26, 2026Total Assets
41.79MUSDvs all stocks (USD)
Total Current Assets
39.89MUSDFY2025 · Dec 31, 2025Total Liabilities
20.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
11.19MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.08MUSDFY2025 · Dec 31, 2025Cash
639.00KUSDFY2025 · Dec 31, 2025Cash Equivalents
20.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.91MUSDFY2025 · Dec 31, 2025Other Short-term Investments
15.47MUSDFY2025 · Dec 31, 2025Accounts Payable
867.00KUSDFY2025 · Dec 31, 2025Short-term Debt
3.77MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.56MUSDFY2025 · Dec 31, 2025Long-term Debt
11.19MUSDFY2025 · Dec 31, 2025Common Stock (Book)
121.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-260.23MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
21.52MUSDvs all stocks (USD)
52-Week Low
2.62USDUpdated Sep 26, 202652-Week High
8.64USDUpdated Sep 26, 202652-Week Change
148.03%vs all stocks
Beta
2.25xvs all stocks
50-Day MA
7.27USDUpdated Sep 26, 2026200-Day MA
5.35USDUpdated Sep 26, 2026Avg 10-Day Volume
1.60MSharesUpdated Sep 26, 2026Avg 30-Day Volume
1.59MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-1.66USDUpdated Sep 26, 2026Other Income / Expense
-444.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.95×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.95Industry median: 5.71Industry P5: 1.02Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.70
Altman Z-Score 10.88: safe zoneNotable
Altman Z-Score: 10.88
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Immix Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule